[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Krystal Biotech Inc (KRYS)

Krystal Biotech Inc (KRYS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,223,699
  • Shares Outstanding, K 29,480
  • Annual Sales, $ 389,130 K
  • Annual Income, $ 204,830 K
  • EBIT $ 179 M
  • EBITDA $ 185 M
  • 60-Month Beta 0.50
  • Price/Sales 23.16
  • Price/Cash Flow 41.94
  • Price/Book 7.06

Options Overview Details

View History
  • Implied Volatility 34.41% (-1.83%)
  • Historical Volatility 35.64%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 59.65% on 10/31/25
  • IV Low 34.41% on 05/12/26
  • Expected Move (DTE 3) 8.88 (2.86%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 166
  • Volume Avg (30-Day) 326
  • Put/Call OI Ratio 0.62
  • Today's Open Interest 6,452
  • Open Int (30-Day) 5,229
  • Expected Range 301.43 to 319.19

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.81
  • Number of Estimates 4
  • High Estimate $1.98
  • Low Estimate $1.59
  • Prior Year $1.29
  • Growth Rate Est. (year over year) +40.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
251.97 +23.15%
on 05/04/26
315.17 -1.54%
on 05/12/26
+51.31 (+19.81%)
since 04/10/26
3-Month
242.00 +28.23%
on 03/31/26
315.17 -1.54%
on 05/12/26
+40.05 (+14.82%)
since 02/12/26
52-Week
122.80 +152.70%
on 05/23/25
315.17 -1.54%
on 05/12/26
+170.88 (+122.56%)
since 05/12/25

Most Recent Stories

More News
Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

PITTSBURGH, May 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2026 Health Care Conference...

KRYS : 310.31 (-0.82%)
Krystal Biotech Announces First Quarter 2026 Financial and Operating Results

$116.4 million in 1Q VYJUVEK global revenue and $846.7 million since launch Enrollment complete in KB803 (corneal abrasions in DEB patients) registrational study On track for KB803 and KB801 (NK)...

KRYS : 310.31 (-0.82%)
Krystal Biotech Reports Revenue Growth but Reimbursement Talks Still Linger in Key Markets

Barchart Research What to Expect from KRYS Earnings KRYS Generated May 1, 2026 Current Price $266.04 EPS Estimate $$1.45 Consensus Rating Strong Buy Average Move 7.05% Krystal Biotech Reports Revenue Growth...

KRYS : 310.31 (-0.82%)
Krystal Biotech Reports Revenue Growth but Reimbursement Talks Still Linger in Key Markets

Barchart Research What to Expect from KRYS Earnings KRYS Generated May 1, 2026 Current Price $266.04 EPS Estimate $$1.45 Consensus Rating Strong Buy Average Move 7.05% Krystal Biotech Reports Revenue Growth...

KRYS : 310.31 (-0.82%)
Krystal Biotech to Present at Upcoming Scientific Conferences

PITTSBURGH, April 30, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs at upcoming scientific...

KRYS : 310.31 (-0.82%)
Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026

PITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its first quarter 2026 financial results on Monday, May...

KRYS : 310.31 (-0.82%)
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services

Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (Nasdaq: KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its...

KRYS : 310.31 (-0.82%)
PVLA : 125.79 (+3.03%)
Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference

PITTSBURGH, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference...

KRYS : 310.31 (-0.82%)
Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

$107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment...

KRYS : 310.31 (-0.82%)
Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its fourth quarter and full year 2025 financial results...

KRYS : 310.31 (-0.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States.

See More

Key Turning Points

3rd Resistance Point 321.09
2nd Resistance Point 318.13
1st Resistance Point 314.22
Last Price 310.31
1st Support Level 307.35
2nd Support Level 304.39
3rd Support Level 300.48

See More

52-Week High 315.17
Last Price 310.31
Fibonacci 61.8% 241.68
Fibonacci 50% 218.99
Fibonacci 38.2% 196.29
52-Week Low 122.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.